Research Matters: Why Quality Research Has Become Essential Capital Markets Infrastructure

Historically, equity research was an important part of the capital markets ecosystem. Analysts helped investors understand businesses, evaluate opportunities, benchmark peers, and interpret financial performance. Research provided the bridge between companies seeking capital and investors looking to invest. Today, that link is almost non-existent.

Since the dotcom bubble, research coverage has declined dramatically, particularly in the SME space. In Europe, the MiFID II decoupling of trading commissions, shrinking research budgets, and the continued rise of passive investing have weakened the economics of the research business. Faced with limited resources, brokers have steadily concentrated coverage on larger companies, leaving thousands of public companies with little or no coverage at all.

The impact has been significant. According to industry surveys, 82% of UK fund managers reported seeing less coverage of small and mid-cap companies after MiFID II, and 79% said the decline had hurt liquidity. More than half of smaller listed companies report a reduction in analyst coverage versus pre-reform levels, and some estimates suggest research spending has fallen by more than 50%.

One can debate how much regulation alone drove this. But there is growing consensus that coverage across public markets has deteriorated and that investors, issuers, and exchanges are all feeling the consequences.

Those consequences are even more pronounced outside the world's major markets. Investors in New York, London, Toronto, or Sydney cannot be expected to know every listed company across Central Europe, the Middle East, Central Asia, Africa, or Latin America. They depend on intermediaries to identify opportunities, provide context, and help evaluate risk. Research serves that function. Without it, many companies are invisible despite the quality of their business, management team, or growth prospects.

Increasingly, research should be viewed not as an investor relations service but as capital markets infrastructure.

Exchanges invest heavily in trading systems, surveillance, regulation, and listing standards because these support market quality. Research serves a similarly vital purpose: it provides the context that lets investors discover companies, understand opportunities, and allocate capital efficiently. Without that layer, even well-regulated, technologically advanced markets struggle to attract attention and liquidity.

Regulators are beginning to recognize the problem as well. Recent reforms adopted through the European Union's Listing Act aim to address the decline in research coverage by introducing greater flexibility around research payment arrangements while also establishing standards and a code of conduct for issuer-sponsored research. The goal is not to promote individual companies, but to improve the availability, quality, and transparency of the information investors receive.

That distinction matters because the debate surrounding issuer-sponsored research is often framed incorrectly. For many companies, particularly smaller issuers and those listed in less-followed markets, the choice is not between independent research and sponsored research. The choice is between sponsored research and no research at all. As traditional sell-side coverage continues to contract, alternative models have appeared to fill a growing information gap that would otherwise leave many companies overlooked by investors.

Not all sponsored research is created equal. The most effective providers understand that their role is not to promote stocks or produce marketing material disguised as analysis. Their responsibility is to provide rigorous, transparent, and professionally prepared research that helps investors allocate capital with confidence. Investors are fully capable of evaluating research when sponsorship arrangements are clearly disclosed and appropriate standards are maintained. Ultimately, credibility remains the most valuable asset any research provider possesses.

The discussion should therefore move beyond who pays for research and focus on a more fundamental question: how capital markets ensure investors have access to the information they need to make informed decisions. Investors need information, companies need visibility, exchanges need engaged investors, and markets need efficient price discovery. Those aims become harder to achieve when research coverage disappears. In today's market environment, quality research is no longer a luxury. It has become an essential part of market infrastructure and an important driver of visibility, liquidity, and long-term capital formation.

For issuers in less-followed markets, the practical implications are straightforward

Visibility is not automatic. A strong business, a solid balance sheet, and a capable management team mean little if no analyst is telling that story to global investors. In markets where sell-side coverage is thin, a fundamentally sound company can remain effectively invisible. Research is what closes that gap.

International coverage works at home, too. Coverage by global analysts is not only a channel to foreign capital. It signals credibility to domestic investors, lenders, and counterparties; it draws local institutions that take their cue from external validation; and it sharpens liquidity and price discovery in the company's own market. For an issuer, being seen abroad raises its standing at home.

The real choice is research or silence. For most smaller and less-followed issuers, the decision is not between independent and sponsored research — it is between sponsored research and no research at all. Declining to engage does not preserve neutrality; it simply leaves the company uncovered.

Quality and disclosure are the whole point. Sponsored research only works when it is rigorous, transparent, and clearly disclosed. Promotional material dressed up as analysis destroys the one asset that makes research useful: credibility. Issuers should choose providers held to professional standards, not those offering the most flattering narrative.

Coverage underpins liquidity and price discovery. Research does more than support the share price. It gives investors the context to value a company properly, which over time sustains trading activity, fairer pricing, and broader access to capital.

For exchanges and regulators, research is infrastructure. Like surveillance systems and listing standards, it deserves deliberate support through clear frameworks — the EU Listing Act's code of conduct for issuer-sponsored research being one model worth watching.

Originally published on LinkedIn.